Type 2 diabetes remission trajectories and variation in risk of diabetes complications: a population-based cohort study: Type 2 diabetes, remission trajectories and diabetes complications
Type 2 diabetes remission trajectories and variation in risk of diabetes complications: a population-based cohort study: Type 2 diabetes, remission trajectories and diabetes complications
Biochemical remission of type 2 diabetes is achievable through dietary changes, physical activity and subsequent weight loss. We aim to identify distinct diabetes remission trajectories in a large population-based cohort over seven-years follow-up and to examine associations between remission trajectories and diabetes complications. Group-based trajectory modelling examined longitudinal patterns of HbA1c level (adjusting for remission status) over time. Multivariable Cox models quantified the association between each remission trajectory and microvascular complications, macrovascular complications, cardiovascular (CVD) events and all-cause mortality. Four groups were assigned. Group 1 (8,112 [13.5%]; achieving HbA1c <48 mmol/mol (6.5%) followed by increasing HbA1c levels); Group 2 (6,369 [10.6%]; decreasing HbA1c levels >48 mmol/mol (6.5%)); Group 3 (36,557 [60.6%]; stable high HbA1c levels); Group 4 (9,249 [15.3%]; stable low HbA1c levels (<48mmol/mol or <6.5%)).Compared to Group 3, Groups 1 and 4 had lower risk of microvascular complications (aHRs (95% CI): 0.65 (0.61-0.70), p-value <0.001;0.59 (0.55-0.64) p-value<0.001, respectively)) , macrovascular complications (aHRs (95% CI): 0.83 (0.75-0.92), p-value<0.001; 0.66 (0.61-0.71), p-value<0.001) and CVD events (aHRs (95% CI): 0.74(0.67-0.83), p-value<0.001; 0.67(0.61-0.73), p-vlaue<0.001). Risk of CVD outcomes were similar for Groups 2 and 3. Compared to Group 3, Group 1 (aHR: 0.82(95% CI: 0.76-0.89)) had lower risk of mortality, but Group 4 had higher risk of mortality (aHR: 1.11(95% CI: 1.03-1.19)). Risk of CVD outcomes vary by pattern of remission over time, with lowest risk for those in remission longer. People who achieve remission, even for shorter periods of time, continue to benefit from this lower exposure to hyperglycaemia, which may, in turn, lower the risk of CVD outcomes including mortality.
Dambha-Miller, Hajira
58961db5-31aa-460e-9394-08590c4b7ba1
Hounkpatin, Hilda
5612e5b4-6286-48c8-b81f-e96d1148681d
Stuart, Beth
b9f62686-75f1-49d0-8c79-7d3feca1cb14
Farmer, Andrew
c384123c-1276-4d06-a2b5-d5419bd83b1d
Griffin, Simon
82ce3f76-cd32-4125-8b46-0cae8f1e2278
Dambha-Miller, Hajira
58961db5-31aa-460e-9394-08590c4b7ba1
Hounkpatin, Hilda
5612e5b4-6286-48c8-b81f-e96d1148681d
Stuart, Beth
b9f62686-75f1-49d0-8c79-7d3feca1cb14
Farmer, Andrew
c384123c-1276-4d06-a2b5-d5419bd83b1d
Griffin, Simon
82ce3f76-cd32-4125-8b46-0cae8f1e2278
Dambha-Miller, Hajira, Hounkpatin, Hilda, Stuart, Beth, Farmer, Andrew and Griffin, Simon
(2023)
Type 2 diabetes remission trajectories and variation in risk of diabetes complications: a population-based cohort study: Type 2 diabetes, remission trajectories and diabetes complications.
PLoS ONE.
(In Press)
Abstract
Biochemical remission of type 2 diabetes is achievable through dietary changes, physical activity and subsequent weight loss. We aim to identify distinct diabetes remission trajectories in a large population-based cohort over seven-years follow-up and to examine associations between remission trajectories and diabetes complications. Group-based trajectory modelling examined longitudinal patterns of HbA1c level (adjusting for remission status) over time. Multivariable Cox models quantified the association between each remission trajectory and microvascular complications, macrovascular complications, cardiovascular (CVD) events and all-cause mortality. Four groups were assigned. Group 1 (8,112 [13.5%]; achieving HbA1c <48 mmol/mol (6.5%) followed by increasing HbA1c levels); Group 2 (6,369 [10.6%]; decreasing HbA1c levels >48 mmol/mol (6.5%)); Group 3 (36,557 [60.6%]; stable high HbA1c levels); Group 4 (9,249 [15.3%]; stable low HbA1c levels (<48mmol/mol or <6.5%)).Compared to Group 3, Groups 1 and 4 had lower risk of microvascular complications (aHRs (95% CI): 0.65 (0.61-0.70), p-value <0.001;0.59 (0.55-0.64) p-value<0.001, respectively)) , macrovascular complications (aHRs (95% CI): 0.83 (0.75-0.92), p-value<0.001; 0.66 (0.61-0.71), p-value<0.001) and CVD events (aHRs (95% CI): 0.74(0.67-0.83), p-value<0.001; 0.67(0.61-0.73), p-vlaue<0.001). Risk of CVD outcomes were similar for Groups 2 and 3. Compared to Group 3, Group 1 (aHR: 0.82(95% CI: 0.76-0.89)) had lower risk of mortality, but Group 4 had higher risk of mortality (aHR: 1.11(95% CI: 1.03-1.19)). Risk of CVD outcomes vary by pattern of remission over time, with lowest risk for those in remission longer. People who achieve remission, even for shorter periods of time, continue to benefit from this lower exposure to hyperglycaemia, which may, in turn, lower the risk of CVD outcomes including mortality.
Text
PONE-D-23-05345R1_FTC
More information
Accepted/In Press date: 29 August 2023
Identifiers
Local EPrints ID: 481443
URI: http://eprints.soton.ac.uk/id/eprint/481443
ISSN: 1932-6203
PURE UUID: 1f3cdf6a-51e7-4fbe-b1f6-f56965353c07
Catalogue record
Date deposited: 29 Aug 2023 16:46
Last modified: 18 Mar 2024 03:50
Export record
Contributors
Author:
Beth Stuart
Author:
Andrew Farmer
Author:
Simon Griffin
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics